The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended a liquid formulation of glibenclamide (Amglidia) for the treatment of neonatal diabetes. It said the sulphonylurea product would be available as an oral suspension (0.6 mg/ml and 6 mg/ml), to help avoid the off-label use of crushed glibenclamide tablets mixed with water. “This ...
New form of glibenclamide gets EU nod for neonatal diabetes
By Mardi Chapman
1 Mar 2018